- Home
- VERV
as 07-26-2024 4:00pm EST
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 601.2M | IPO Year: | 2021 |
| Target Price: | $33.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.59 - $20.58 | Next Earning Date: | 08-08-2024 |
| Revenue: | $16,049,000 | Revenue Growth: | 379.79% |
| Revenue Growth (this year): | 32.56% | Revenue Growth (next year): | -40.51% |
Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ashe Andrew D. | VERV | See Remarks | May 14 '24 | Buy | $6.26 | 76,000 | $475,760.00 | 342,509 | SEC Form 4 |
| Nickerson Joan | VERV | Chief Administrative Officer | Apr 1 '24 | Sell | $8.24 | 1,514 | $12,475.36 | 8,659 | SEC Form 4 |
| Yeshwant Krishna | VERV | Director10% Owner | Dec 1 '23 | Buy | $10.00 | 1,800,000 | $18,000,000.00 | 1,800,000 | SEC Form 4 |
| Dorval Allison | VERV | Chief Financial Officer | Nov 29 '23 | Sell | $11.45 | 554 | $6,343.30 | 4,060 | SEC Form 4 |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk
Insider Monkey
18 days ago
Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?
GlobeNewswire
25 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Simply Wall St.
a month ago
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
GlobeNewswire
2 months ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Verve Therapeutics Names Troy Lister Chief Scientific Officer
GlobeNewswire
2 months ago
Verve Therapeutics Announces Leadership Update
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.